Transcatheter Pacing System

Clinical Evidence

Primary pre-specified safety, effectiveness, and long-term safety objectives were met (n = 726)1,2

  • 96% of patients experienced no major complications by 12 months follow-up2
    • 0 dislodgements or systemic infections
    • Low (0.4%) revision rate
  • Pacing thresholds remained low and stable pacing thresholds through twelve months1
    • Yielding an estimated battery longevity on average of 12.1 years

Lower rate of complications

48% fewer major complications than traditional pacemakers*2

Pacing Capsule

Initial real-world experience confirms the low complication rate of IDE trial (n = 1349)3

  • High implant success rate (99.7%)
  • Low major complication rate at 30 days (1.56%)
    • Low dislodgement rate (0.07%)
    • Low infection rate (0.15%)


Historical cohort comprised of 2,667 patients from 6 trials of commercially available technology. (HR: 0.46, 95%CI: 0.30-0.72; P-value <0.001). To adjust for difference in patient populations, propensity matching to a subset of the historical control confirmed a reduction in major complications with Micra.


Reynolds DW, Duray GZ, Omar R, et al. A Leadless Intracardiac Transcatheter Pacing System. N Engl J Med. February 11, 2016;374(6):533-541.


Duray GZ, Ritter P, El-Chami M, et al. Long-term performance of a transcatheter pacing system: 12-Month results from the Micra Transcatheter Pacing Study. Heart Rhythm. Published online February 10, 2017.


Roberts P, et al. Real-World Experience with a Leadless Pacemaker: A Comparison to the Initial Experience. Presented at: APHRS/JHRS 2017; September 16, 2017; Yokohama, Japan.